ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VYNE VYNE Therapeutics Inc

2.4314
-0.0386 (-1.56%)
Last Updated: 11:56:57
Delayed by 15 minutes

Period:

Draw Mode:

Volume 8,109
Bid Price 2.42
Ask Price 2.58
News -
Day High 2.54

Low
1.67

52 Week Range

High
8.81

Day Low 2.4314
Company Name Stock Ticker Symbol Market Type
VYNE Therapeutics Inc VYNE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0386 -1.56% 2.4314 11:56:57
Open Price Low Price High Price Close Price Prev Close
2.47 2.4314 2.54 2.47
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
110 8,109 $ 2.49 $ 20,168 - 1.67 - 8.81
Last Trade Time Type Quantity Stock Price Currency
11:57:16 1 $ 2.5642 USD

VYNE Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
35.25M 14.10M - 424k -28.45M -2.02 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VYNE Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VYNE Message Board. Create One! See More Posts on VYNE Message Board See More Message Board Posts

Historical VYNE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.262.802.242.52107,7740.17147.58%
1 Month3.133.172.242.7697,411-0.6986-22.32%
3 Months1.803.171.772.49109,8030.631435.08%
6 Months2.404.48081.672.69266,3460.03141.31%
1 Year4.298.811.673.07150,036-1.86-43.32%
3 Years93.6098.461.6719.50715,650-91.17-97.40%
5 Years106.56237.601.6796.011,250,994-104.13-97.72%

VYNE Therapeutics Description

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds.

Your Recent History

Delayed Upgrade Clock